The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gomez, C. M.
Right arrow Articles by Richman, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomez, C. M.
Right arrow Articles by Richman, D. P.

The Journal of Immunology, Vol 135, Issue 1 234-241, Copyright © 1985 by American Association of Immunologists

ARTICLES

Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis

CM Gomez and DP Richman

To study the characteristics of the individual autoantibodies that are important in the development of an autoimmune disease, we produced 26 anti-acetylcholine receptor (anti-AChR) monoclonal antibodies (mcAb) and studied the experimental autoimmune myasthenia gravis (EAMG) induced by a number of them. The mcAb reactive with mammalian acetylcholine receptor (M-AChR) exhibited a wide range of dissociation rates from in situ M-AChR of motor endplates. All anti-M-AChR mcAb were capable of producing at least some degree of histopathologic change at the endplate indicative of EAMG, but their potencies varied markedly. One mcAb induced, even at large doses, only minor macrophage invasion without clinical or electromyographic effect. Others induced severe EAMG, and even death, at 1/200th the dose. Low potency was associated with high rate of mcAb dissociation from antigen. High potency was associated with intermediate avidity, not high avidity. These observations suggest that in EAMG, and perhaps in myasthenia gravis, the characteristics of the individual antibodies making up the autoimmune response can determine the severity of the autoimmune disease.


This article has been cited by other articles:


Home page
 Arch NeurolHome page
C. Amdahl, E. H. Alseth, N. E. Gilhus, H. L. Nakkestad, and G. O. Skeie
Polygenic Disease Associations in Thymomatous Myasthenia Gravis
Arch Neurol, December 1, 2007; 64(12): 1729 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Saoudi, I. Bernard, A. Hoedemaekers, B. Cautain, K. Martinez, P. Druet, M. De Baets, and J.-C. Guery
Experimental Autoimmune Myasthenia Gravis May Occur in the Context of a Polarized Th1- or Th2-Type Immune Response in Rats
J. Immunol., June 15, 1999; 162(12): 7189 - 7197.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Balasa, C. Deng, J. Lee, P. Christadoss, and N. Sarvetnick
The Th2 Cytokine IL-4 Is Not Required for the Progression of Antibody-Dependent Autoimmune Myasthenia Gravis
J. Immunol., September 15, 1998; 161(6): 2856 - 2862.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
B. Balasa, C. Deng, J. Lee, L. M. Bradley, D. K. Dalton, P. Christadoss, and N. Sarvetnick
Interferon gamma  (IFN-gamma ) Is Necessary for the Genesis of Acetylcholine Receptor-induced Clinical Experimental Autoimmune Myasthenia gravis in Mice
J. Exp. Med., August 4, 1997; 186(3): 385 - 391.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
C. M. Gomez, R. Maselli, J. E. Gundeck, M. Chao, J. W. Day, S. Tamamizu, J. A. Lasalde, M. McNamee, and R. L. Wollmann
Slow-Channel Transgenic Mice: A Model of Postsynaptic Organellar Degeneration at the Neuromuscular Junction
J. Neurosci., June 1, 1997; 17(11): 4170 - 4179.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1985 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1985 by The American Association of Immunologists, Inc. All rights reserved.